Vorsetuzumab mafodotin

DB15352Investigational

Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).

Mechanism: Pharmacologically active on CD70 antigen
Curator reviewed
Code names: SGN-75

Resolves to

Compound

UNII699619YVTQCAS1165741-01-4

Targets

P32970CD70

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vorsetuzumab mafodotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account